Citations

Clear

12617 citation(s) found for "Go, John R".

Recent Progress in the Field of Artificial Organs
Curran, Brett F., Shah, Aakash M., Curran, Brett , Ursoleo, Jacopo D’Andria , Shah, Aakash M., Treffalls, John A.

Mayo Clinic

Artificial Organs | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/aor.70235 Get It

Beyond Binary PTEN Loss: Integrating Genomics, Long-Term Outcomes, and AI-Assisted Digital Pathology to Define Actionable PTEN Deficiency in Prostate Cancer.
Zarka, Jabra, Pessoa, Rodrigo Rodrigues , Gupta, Sounak , Chen, Eric, Greipp, Patricia, Orme, Jacob J., Karnes, R. Jeffrey, Cheville, John C. , Heath, Elisabeth, Zarka, Jabra , Greipp, Patricia T. , Childs, Daniel S. , Orme, Jacob J. , Karnes, R. Jeffrey

Mayo Clinic

International Journal of Cancer Care and Delivery | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.53876/001a.129758 Get It

Colony‐stimulating factor 1 receptor‐related disorder: Clinical variability of biallelic variants
Milanowski, Łukasz , Santos, Mara Lucia Schmitz Ferreira , Teive, Helio G., Fink, John K., Orthmann‐Murphy, Jennifer, Arnold, Kaley, Wszołek, Zbigniew K. , Wszolek, Z.K. , Milanowski, Łukasz M , Souza, Josiane , Teive, Hélio Afonso Ghizoni , Fink, John K. , Orthmann‐Murphy, Jennifer , Dulski, Jarosław , Group, CSF1R‐RD Study

Mayo Clinic

Developmental Medicine & Child Neurology | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/dmcn.70515 | PMID 42706750 Get It

Abstract Biallelic colony‐stimulating factor 1 receptor ( CSF1R ) variants are a major cause of early‐onset CSF1R ‐related disorder (CSF1R‐RD), although fewer than 30 cases have been reported and genotype–phenotype correlations remain unclear. The aim of this study was to characterize the clinical, radiological, and genetic features of patients with brain abnormalities, neurodegeneration, and dysosteosclerosis (BANDDOS). Six patients with biallelic CSF1R variants underwent detailed clinical, neurological, and magnetic resonance imaging evaluation. Three siblings with a homozygous p.Gly585Val variant showed marked phenotypic variability, ranging from severe childhood‐onset neurodegeneration to an asymptomatic presentation, all with white matter abnormalities. Three unrelated patients carried different biallelic CSF1R variants and presented with congenital skeletal abnormalities or early‐onset neurological disease of variable severity. These cases broaden the phenotypic spectrum of biallelic CSF1R‐RD and demonstrate that disease severity cannot be predicted solely by genotype, suggesting an important role for genetic or environmental modifiers.
Metabolomic correlates of intravenous racemic ketamine in treatment-resistant major depressive disorder: the Bio-K/NNDC multicenter trial
Singh, Balwinder , MahmoudianDehkordi, Siamak , Vande Voort, Jennifer L., Parikh, Sagar V., Achtyes, Eric D. , Bobo, William V. , Greden, John F., Scaini, Giselli, Tye, Susannah J. , Frye, Mark A. , Kaddurah-Daouk, Rima, V Bobo, William , Tye, Susannah J , Singh, Balwinder , Voort, Jennifer L. Vande , Parikh, Sagar V. , Goes, Fernando , Scaini, Giselli , Kaddurah‐Daouk, Rima

Mayo Clinic

The World Journal of Biological Psychiatry | September 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-15

10.1080/15622975.2026.2724510 | PMID 42702010 Get It

Nuclear Cathepsin L Remodels the Replication Machinery to Create a Therapeutic Vulnerability in Ovarian Cancer
Jin, Ling, Balakrishnan, Karthik , Hou, Xiaonan , VanBlaricom, Jamison L., Lee, Sun-Hee, Oberg, Ann L. , Weroha, John, Shridhar, Viji, Thirusangu, Prabhu , Jin, Ling, Rao, Shruti , Balakrishnan, Karthik, Lee, Sun-Hee , Kaufmann, Scott H. , Bakkum‐Gamez, Jamie N. , Shridhar, Viji

Mayo Clinic

No container title available | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.02.748933 | PMID 42922689 Get It

Abstract Therapeutic resistance in ovarian cancer is frequently driven by persistent replication stress, yet the molecular mechanisms that convert replication stress into a therapeutically exploitable vulnerability remain incompletely understood. Here, we identify drug-induced nuclear cathepsin L (nCTSL) as a previously unrecognized regulator of replication stress and DNA repair. Clofarabine (CLF) combined with the ATR inhibitor AZD6738, or the CHK1 inhibitor prexasertib promoted nuclear accumulation of CTSL, where it remodeled the replication machinery through degradation of CCNE1, MCM3, MCM6, and geminin, accompanied by loss of RAD51 and 53BP1 and increased γH2AX and phospho-RPA2. DNA fiber analysis demonstrated marked inhibition of replication fork progression following CLF-based combinations, whereas CTSL depletion accelerated fork progression and abolished therapy-induced replication stress. Reconstitution with the nuclear M1F CTSL isoform restored replication restraint, confirming a direct role for nuclear CTSL in regulating replication dynamics. GFP-based DNA repair reporter assays further revealed that CLF-based combinations suppress DNA repair competence in a CTSL-dependent manner, indicating that nuclear CTSL couples replication stress amplification with functional inhibition of repair pathways. Functionally, CLF-based combinations selectively targeted transformed fallopian tube secretory epithelial cells while sparing non-transformed counterparts, demonstrated broad activity in patient-derived ovarian cancer ascites spheroids, and significantly inhibited tumor growth and prolonged survival in vivo . Collectively, our findings identify nuclear CTSL as a mechanistic driver of replication stress that remodels the replication machinery, impairs DNA repair, and creates a therapeutically exploitable vulnerability in ovarian cancer. We propose that nuclear CTSL promotes a transition from replication competence to replication catastrophe, thereby establishing a conceptual framework for biomarker-guided therapeutic strategies targeting CTSL-dependent replication stress.
Longitudinal Data from a Large, Multi-Target Stool DNA Colorectal Cancer Screening Program
Garg, Sushil Kumar , Hintz, Carley F , Kolarik, Hannah J , Mau, Brayden , Hubers, Jeffrey , Arce, Victor, Ebner, Derek W. , Gurudu, Suryakanth, Bi, Yan , Greenwood, Jason D. , Chaudhary, Rajeev, Hubers, Jeffery , Gurudu, Suryakanth R, Greenwood, Jason , Kisiel, John B , Ebner, Derek , Kolarik, Hannah , Arce, Victor, Kisiel, John B.

Mayo Clinic

American Journal of Gastroenterology | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004196 | PMID 42690929 Get It

Background & Aims: Multi-target stool DNA (mt-sDNA) is an established stool-based colorectal cancer screening test, yet long-term performance is not well-described. We evaluated follow-up colonoscopy rates & quality, neoplasia yield, and repeat-testing adherence over 10 years with an integrated screening program. Methods: We assembled a retrospective cohort of mt-sDNA tests (September 2014–July 2025) within a multi-site health system. A validated large-language-model pipeline extracted colonoscopy, pathology, and quality endpoints from free-text reports. Detection outcomes (adenoma detection rate, advanced neoplasia, modified advanced adenoma, sessile serrated lesion (SSL), and negative exams) were calculated among high-quality exams; adenocarcinoma, bowel preparation adequacy, and cecal intubation rate (CIR) used all screening exams. We assessed colonoscopy completion ≤1 year after positive mt-sDNA, follow-up colonoscopy findings, findings by time-to-colonoscopy, and adherence to repeat mt-sDNA after negative result. Results: Among 148,624 tests in 110,410 individuals, positivity was 13.6%. Of 19,506 positives, 65.1% completed colonoscopy within 12 months (median 82 days). Colonoscopy after a positive mt-sDNA had high yield: advanced adenoma diagnosis was 30.7%; adenocarcinoma was 1.3%. Of patients who had colonoscopy within 3 years of a negative mt-sDNA test, 45.2% had adenoma/serrated lesion, 9.3% had advanced adenoma and 0.5% had colon cancer. Adenoma detection rate after positive mt-sDNA (>50%) exceeded specialty society quality benchmarks and increased over time; Longer intervals (>6 months) to colonoscopy after a positive test were associated with higher advanced adenoma (trend P=0.001).After an initial negative mt-sDNA, only 35.3% were screened again by mt-sDNA testing within 3 years. Conclusions: Over a decade,mt-sDNA screening achieved high colonoscopy qualitybut revealed critical gaps in the care cascade. One-third of positive tests lacked timely follow-up and nearly two-thirds of negative tests were not repeated on schedule, suggesting opportunities for system-level interventions.
Trauma-Associated Optic Neuritis in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Case Series
Choi, David, Chen, John J. , Danesh-Meyer, Helen V., Chen, John J , Choi, David, Danesh‐Meyer, Helen V.

Mayo Clinic

Neuro-Ophthalmology | August 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-7

10.1080/01658107.2026.2726813 Get It

Prognostic Value of Artificial Intelligence ECG–Derived Diastolic Function in Surgical Aortic Valve Replacement
Sawma, Tedy , Schaff, Hartzell V. , Danesh, Sina , Arghami, Arman , Lee, Eunjung , Aslahishahri, Masoomeh, Stulak, John, Greason, Kevin L. , Dearani, Joseph A. , López-Jiménez, Francisco , Friedman, Paul A. , Oh, Jae K. , Dearani, Joseph A. , Greason, Kevin , Sabbah, Michael S. , Attia, Zachi I , Oh, Jae K. , Crestanello, Juan A , Lopez-Jimenez, Francisco , Arghami, Arman , Schaff, Hartzell , Stulak, John M., Pislaru, Sorin V. , Attia, Zachi I. , Crestanello, Juan A.

Mayo Clinic

Journal of the American Heart Association | August 31, 2026 | Volume: 15 | Issue: 19 | Pages: No page available

10.1161/jaha.126.050492 | PMID 42669926 Get It

Background Diastolic dysfunction is common in patients with aortic stenosis and may influence outcomes following surgical aortic valve replacement. We aimed to examine the association of preoperative artificial intelligence (AI)‐generated diastolic function grades with early and late outcomes following aortic valve replacement and how postoperative progression influence prognosis. Methods We identified 5503 patients undergoing aortic valve replacement between 2000 and 2023. Diastolic function was assessed using a validated deep‐learning AI model applied to 12‐lead ECGs done preoperatively and on postoperative follow‐up. Diastolic grades were classified by AI into Grades 1 to 3. Longitudinal trend analyses and multivariable regression models were used to assess study end points. Results Among 5503 patients (mean age 72.4±10.8 years; 39% female), higher AI ECG diastolic grades were associated with greater comorbidity burden, including diabetes, renal disease, and heart failure. AI ECG diastolic Grade 3 was independently associated with higher in‐hospital mortality (odds ratio, 2.5; P =0.007) and other complications. At 5‐year follow‐up, patients with Grade 3 showed the least improvement in diastolic function by both ECG and echocardiography. Grades 2 and 3 diastolic function at baseline were independently associated with increased late mortality (hazard ratio, 1.3 and 2.45, respectively; both P <0.001). Additionally, lack of improvement in AI ECG diastolic grade by 1 year was also independently associated with late mortality. Conclusions AI ECG–derived diastolic function grades strongly correlates with early complications and long‐term mortality and diastolic progression after aortic valve replacement. AI ECG provides a powerful, noninvasive tool for risk stratification and longitudinal monitoring of patients with aortic stenosis.
Artificial Intelligence–Enabled Acquisition and Interpretation for Screening Aortic Stenosis
Naser, Jwan A., Kane, Conor J. , Kovac, Jude L., Greason, Christie, Killalea, Méabh M., Gulati, Mayari A., Jackson, John I. , Borgeson, Jordan, Schonfeld, Daniel A., Crestanello, Maria M., Zacher, Jessica, Çamalan, Seda , Thaden, Jeremy J. , Anand, Vidhu, Nkomo, Vuyisile T., Padang, Ratnasari , Chao, Chieh-Ju, Pellikka, Patricia A., Lopez-Jimenez, Francisco, Friedman, Paul A., Oh, Jae K., Kane, Garvan C., Attia, Zachi I., Pislaru, Sorin V., Bird, Jared G., Tsaban, Gal, Malins, Jeffrey G. , Poterucha, Timothy J. , Lee, Eunjung , Naser, Jwan A. , Kovac, Jude Laures, Greason, Christie, Killalea, Méabh Maria, Gulati, Mayari A., Borgeson, Jordan, Schonfeld, Daniel Andres, Anisuzzaman, DM , Crestanello, Maria Mercedes, Anand, Vidhu , Nkomo, Vuyisile T. , Poterucha, Timothy Joseph , Chao, Chieh‐Ju , Pellikka, Patricia A. , López-Jiménez, Francisco , Friedman, Paul A. , Oh, Jae K. , Kane, Garvan C. , Attia, Zachi I. , Pislaru, Sorin V. , Tsaban, Gal

Mayo Clinic

JAMA Cardiology | August 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamacardio.2026.3829 | PMID 42661496 Get It

Importance Timely identification of aortic stenosis (AS) is essential for appropriate clinical management, yet screening remains limited by dependence on comprehensive echocardiography and trained imaging personnel. Objective To develop and validate a deep learning algorithm for detection of moderate or greater AS and prospectively evaluate its performance using artificial intelligence (AI)–guided focused cardiac ultrasound (FoCUS) acquired by novice operators. Design, Setting, and Participants This diagnostic study included retrospective algorithm development and validation and prospective evaluation of AI-guided FoCUS across Mayo Clinic sites in the Midwest, Arizona, and Florida. The model was developed using 6753 patients and evaluated in internal validation (n = 852), internal test (n = 844), and validation (n = 1912) cohorts. Performance was assessed on FoCUS acquired by experienced sonographers (n = 602) and prospectively by novice operators (n = 1302). The retrospective model development and validation cohorts comprised studies performed from January 2005 through September 2022. Prospective study was conducted in 2 enrollment periods from June to August 2024 and from June to September 2025. Participants from both periods were combined to comprise the final prospective cohort. Exposure AI-guided FoCUS acquisition and automated deep learning–based assessment for detection of moderate or greater AS. Main Outcomes and Measures Detection of moderate or greater AS. Performance was assessed using area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, and positive predictive value. Results The model demonstrated excellent discrimination in the internal test cohort (AUROC, 0.99; 95% CI, 0.98-1.00) and geographically distinct validation cohorts in Arizona (AUROC, 0.99; 95% CI, 0.97-1.00) and Florida (AUROC, 0.99; 95% CI, 0.96-1.00). Among FoCUS examinations acquired by experienced sonographers, sensitivity was 95% (95% CI, 82-99) and specificity was 97% (95% CI, 95-98). In the prospective novice-operator cohort, 1258 of 1302 examinations (96.6%) were suitable for automated analysis. Sensitivity was 93% (95% CI, 82-99) and specificity was 96% (95% CI, 95-97). Expert review of AI-positive and uninterpretable examinations increased the positive predictive value from 49.4% to 91.1%, with sensitivity of 85.4%. Conclusions and Relevance A deep learning algorithm accurately detected moderate or greater AS across validation cohorts in this study. In prospective evaluation, novice operators were able to acquire AI-guided FoCUS examinations that enabled accurate detection of moderate or greater AS. These findings support a scalable strategy that may expand access to AS detection in settings with limited echocardiography resources.
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia
Noll, Julia Han , Dersh, Devin , Li, Jiang Yuan, Hemani, Humza , Lavorando, Maya, Bartoszek, Robert, Amses, Kevin R. , Jain, Ankita , Minehart, Janna , Shestov, Max A, Camerini, Elena , Loren, Alison W., Woyach, Jennifer A. , Goronzy, Jorg Josef, Kater, Arnon P. , Porter, David L., Bushman, Frederic D, Levine, Bruce L. , June, Carl H. , Long, Meixiao, Weng, Nan‐ping , Diorio, Caroline, Ramirez-Fernandez, Angel , Paruzzo, Luca , Camerini, Elena , Peters, Fleur S , Huang, Xiao , Woyach, Jennifer A , Kater, Arnon P , Ruella, Marco , Byrd, John C , Schuster, Stephen J , Siegel, Donald L , Levine, Bruce L , June, Carl H , Frey, Noelle V , Cohen, Adam D , Garfall, Alfred L , Long, Meixiao , Maus, Marcela V , Weng, Nan-Ping , Fraietta, Joseph A , Bartoszek, Robert L. , Ho, Matthew , Paruzzo, Luca , Shestov, Max, Loren, Alison W. , Goronzy, Jörg J. , Ruella, Marco , Byrd, John C. , Powell, Daniel J. , Gill, Saar , Porter, David L. , Schuster, Stephen J. , Bushman, Frederic D. , Frey, Noelle V. , Cohen, Adam D. , Garfall, Alfred L. , Diorio, Caroline J.

Mayo Clinic

Blood Journal | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2025032274 | PMID 42636161 Get It

CD19-directed CAR T-cells (CTL019) can produce durable remissions in chronic lymphocytic leukemia (CLL), but therapeutic success depends on whether autologous T-cells expand, persist, and retain cytotoxic function after manufacturing. Failure of CLL T-cells is often attributed to exhaustion, although many dysfunctional CLL T-cells retain inflammatory cytokine production. We tested whether this paradox reflects immunosenescence, an aging-like program defined by costimulatory loss, DNA damage, inflammatory secretion, repertoire restriction, and proliferative arrest. In response-linked preinfusion CTL019 products, nonresponders and short partial responders had higher senescence and senescence-associated secretory phenotype (SASP) programs than the functional-responder group, comprising complete responders and partial responders with transformed disease. These programs were detectable before infusion and became more prominent during manufacture in susceptible products. They tracked with weak in vivo CAR T-cell expansion and were associated with inferior survival. Serum proteomics revealed a circulating, CLL-associated SASP-like inflammatory milieu in nonresponders. Flow cytometry and T-cell receptor (TCR) profiling showed that poor responders carried CD27⁻CD28⁻ and KLRG1⁺ CD8 T-cells at apheresis, lower product CD27, and reduced product TCR diversity. Research-manufactured CAR T-cells from treatment-naïve CLL samples displayed the same state, most prominently in CD4 CAR T-cells, with SA-β-gal, p16, p53, DNA damage, depletion of less-differentiated states, and senescence-enriched transcriptomes. Under repeated CD19 stimulation, CLL-derived products reached a proliferative ceiling, and p53-high products lost cytotoxic reserve. Ibrutinib improved proliferative fitness, attenuated senescence-associated features and SASP output in paired patient and direct-exposure assays, and enhanced CAR T-cell expansion in an ibrutinib-resistant CLL model. Together, these data identify immunosenescence as a measurable and functionally consequential barrier to CAR T-cell efficacy in CLL and a candidate for therapeutic modulation.